order
provid
rapid
safe
assay
identif
evalu
coronaviru
replicas
inhibitor
gener
noncytopath
select
replicon
rna
base
human
coronaviru
stabli
maintain
eukaryot
cell
stabl
replicon
rnacontain
cell
line
express
green
fluoresc
protein
gfp
marker
coronaviru
replic
use
test
inhibitori
effect
sever
compound
current
assess
sar
treatment
predict
target
replic
protein
amongst
interferonalpha
cinanserin
display
strongest
inhibitori
activ
interestingli
cinanserin
wellcharacter
serotonin
antagonist
alreadi
undergon
preliminari
clinic
test
human
cinanserin
identifi
candid
inhibitor
sarscov
proteinas
virtual
screen
databas
contain
structur
inform
exist
drug
use
dock
approach
potenti
bind
sarscov
proteinas
subsequ
bind
cinanserin
bacteri
express
sarscov
proteinas
inhibit
enzymat
activ
demonstr
experiment
antivir
activ
cinaserin
evalu
two
tissu
culturebas
assay
first
use
safe
replicon
assay
could
demonstr
strong
inhibitori
activ
cinanserin
second
could
demonstr
strong
inhibit
log
reduct
viru
rna
infecti
particl
sarscov
replic
tissu
cultur
find
demonstr
old
drug
cinanserin
potent
inhibitor
sarscov
replic
illustr
valu
noninfecti
coronaviru
replicon
rna
biosaf
screen
evalu
candid
replicas
inhibitor
recent
develop
revers
genet
system
coronavirus
enabl
gener
autonom
replic
rna
base
recombin
coronaviru
genom
construct
coronavirusbas
replicon
rna
made
use
revers
genet
system
fulllength
cdna
clone
vaccinia
viru
vector
modifi
vaccinia
virusmedi
recombin
introduc
gene
select
marker
neo
hcov
replicas
gene
replac
three
structur
gene
e
two
accessori
gene
report
gene
encod
green
fluoresc
protein
gfp
stabl
cell
line
design
contain
replicon
rna
select
use
cell
line
display
green
fluoresc
marker
coronaviru
replic
figur
replicon
cell
line
use
assess
inhibitori
effect
candid
replicas
inhibitor
without
need
propag
infecti
viru
grade
dose
compound
ad
cell
three
day
report
gene
express
level
determin
use
fluoresc
microscopi
fac
analysi
decreas
report
gene
express
indic
antivir
activ
particular
compound
parallel
cytotox
candid
compound
determin
parent
cell
sever
compound
test
antivir
activ
reduc
level
gfp
express
overal
number
green
fluoresc
cell
figur
titrat
show
inhibit
coronaviru
replic
data
indic
appear
repres
promis
candid
inhibit
coronaviru
replicas
function
furthermor
inhibit
coronaviru
replic
monitor
use
coronaviru
replicon
rnacontain
cell
line
one
main
target
antivir
intervent
coronaviru
proteinas
pro
pro
respons
proteolyt
releas
replic
protein
replicas
precursor
polyprotein
therefor
consid
indispens
viru
replic
order
identifi
candid
pro
inhibitor
homolog
model
bind
pocket
sarscov
pro
base
crystallograph
structur
tgev
proteinas
use
target
screen
silico
screen
compound
deriv
comprehens
medic
chemistri
databas
mol
design
limit
contain
pharmacolog
structur
inform
compound
use
evalu
therapeut
agent
human
cinanserin
wellcharacter
serotonin
antagonist
show
high
score
screen
chosen
experiment
test
first
sarscov
pro
express
e
coli
purifi
enzym
use
demonstr
bind
cinanserin
pro
ii
inhibit
pro
cinanserin
vitro
maximum
inhibit
observ
concentr
data
shown
second
use
cell
assess
inhibitori
activ
cinanserin
tissu
cultur
cell
treat
day
cinanserin
express
gfp
analyz
fac
fluoresc
microscopi
number
green
fluoresc
cell
greatli
reduc
concentr
figur
indic
cinanserin
abl
enter
target
cell
inhibit
coronaviru
replicas
function
final
vero
cell
infect
sarscov
treat
cinanserin
two
day
postinfect
viru
rna
tissu
cultur
supernat
analyz
realtim
rtpcr
figur
addit
titer
infecti
particl
supernat
measur
immunofocu
assay
figur
result
clearli
dosedepend
halfmaxim
inhibit
could
achiev
uml
contrast
maxim
inhibitori
effect
ribavirin
glycyrrhizin
exceed
demonstr
viral
rna
tissu
cultur
supernat
infecti
particl
greatli
reduc
log
unit
studi
use
concept
select
coronaviru
replicon
rna
assess
inhibitori
activ
candid
coronaviru
replicas
inhibitor
shown
stabl
replicon
rnacontain
cell
line
provid
rapid
assay
identif
evalu
coronaviru
replicas
inhibitor
although
replicon
rna
use
studi
base
concept
also
applic
gener
sarscov
replicon
rna
stabl
cell
line
contain
sarscov
replicon
rna
enabl
biosaf
screen
evalu
sarscov
replicas
inhibitor
without
need
grow
infecti
viru
work
support
swiss
nation
scienc
foundat
foundat
switzerland
deutsch
forschungsgemeinschaft
